Many injectable drug products begin development in a vial. Vials are flexible, accommodate a wide range of fill volumes, and can provide a relatively straightforward path through early clinical manufacturing. But as a program advances toward commercialization, sponsors may consider moving from a vial to a prefilled syringe.
Prefilled syringes can simplify administration, reduce product waste, improve dosing accuracy, and provide a pathway toward autoinjectors and other drug delivery devices. However, moving to a prefilled syringe introduces a new container closure system, different product-contact materials, new stability considerations, and additional functional requirements.
Planning the transition early can help sponsors identify compatibility issues before they affect development timelines.
Why Move from a Vial to a Prefilled Syringe?
A prefilled syringe eliminates the need to withdraw drug product from a vial before administration. Instead, the intended dose is supplied in a ready-to-use format. This can provide several advantages:
- Usability – prefilled syringes require less preparation and manipulation, making it easier for patients caregivers
- Greater yield – vials typically contain a greater overfill to account for drug product that cannot be withdrawn during administration. A PFS is often filled closer to its intended dose, increasing the number of doses from a given quantity of drug substance
- Reduced dosing errors
- Quality & sterility – less handling during administration means a reduced risk of contamination
- Competitive advantage – patients have shown preference for autoinjectors and prefilled syringes over traditional vial-and-syringe delivery (Korytkowski et al.).
Selecting Appropriate Prefilled Syringe Components
A prefilled syringe includes several components, including the barrel, plunger stopper, needle or Luer lock, and tip cap or needle shield. Each needs to be compatible with the formulation and intended use.
Questions to consider include:
- What volume needs to be administered?
- Will the product be stored frozen, refrigerated, or at room temperature?
- Does the formulation have known sensitivities to silicone oil, tungsten, or other materials?
- Will the syringe eventually be incorporated into an autoinjector?
- What needle gauge and length are appropriate for the route of administration?
- Is a glass or polymer barrel more appropriate?
- What are the anticipated clinical and commercial manufacturing volumes?
Multiple candidate syringe systems can be evaluated during early compatibility and stability studies before selecting a system for formal qualification.
What to Plan for and Evaluate in a Prefilled Syringe Program
Once a syringe system is selected, several parts of the development program need to be revisited.
Evaluating Drug Product Compatibility with a Prefilled Syringe
A prefilled syringe creates a different product-contact environment than a vial. Components and materials such as silicone oil, residual tungsten, elastomers, and adhesives can potentially affect product quality. For biologics and protein-based therapeutics, silicone oil and tungsten may con-tribute to aggregation or particle formation. Extractables and leachables (E&L) from other compo-nents should also be evaluated.
Each component introduces its own compatibility and design considerations:
- Barrel: Borosilicate glass is common, while COP or COC may be considered for products sensitive to glass delamination or leachable metals. Size must account for fill volume, head-space, and device compatibility.
- Plunger stopper: Material, coating, and dimensions can affect syringe performance, product compatibility, and the E&L profile.
- Needle or Luer lock: Needle gauge and length depend on the route of administration and pa-tient population. Staked-needle adhesives introduce additional E&L considerations.
- Tip cap or needle shield: Must maintain container closure integrity and remain compatible with the drug product and intended storage conditions.
Early compatibility screening can identify unsuitable materials or configurations before a sponsor commits to a syringe system.
Reevaluate Fill Volume and Overfill
Moving from a vial to a prefilled syringe also changes how fill volume is established.
Vials typically contain additional drug product to ensure that the required dose can be withdrawn. With a PFS, the drug is delivered directly from the syringe, allowing the target fill volume to be closer to the intended dose.
That doesn’t mean overfill disappears entirely. Needle dead volume, plunger design, manufacturing variability, and deliverable-volume requirements still need to be considered.
During process development, the appropriate target fill volume should be established and translated into filling parameters and fill-weight acceptance limits.
Plan for New Stability Studies
The PFS introduces new product-contact materials, so stability studies need to evaluate the drug product in the intended syringe system. In addition to product-specific quality attributes such as potency, appearance, particulates, and aggregation, testing should consider syringe-specific characteristics.
For example, break-loose and glide force can be monitored to confirm that the plunger continues to function properly throughout shelf life. Deliverable volume should also be evaluated to ensure that the intended dose can be consistently administered.
For biologics, aggregation and subvisible particle testing can be particularly important because of potential interactions with silicone oil and tungsten.
Sponsors don’t necessarily need to wait until the final commercial stage to begin generating this information. Early compatibility and accelerated stability studies can compare candidate syringe systems before the formal ICH stability program begins.
Reevaluate Container Closure Integrity Testing
Moving to a syringe also changes the container closure integrity testing strategy.
A syringe has multiple potential leak paths across the barrel, plunger, and needle shield or tip cap. As a result, a CCIT method used for a vial may not be appropriate for the new presentation.
Potential approaches include laser-based headspace analysis, vacuum decay, mass extraction, helium leak detection, and other deterministic methods.
The appropriate method depends on the syringe configuration, formulation, fill volume, headspace, and storage conditions. For example, vacuum-based methods may require controls to prevent plunger movement, while laser headspace methods require sufficient headspace within the syringe.
CCIT should therefore be developed and validated for the specific drug product and syringe system.
Planning to Use an Autoinjector? Start Early.
If the eventual goal is an autoinjector, device requirements should be considered while selecting the syringe rather than after the PFS configuration has been finalized.
Device platforms are designed around specific syringe dimensions and operating ranges. Syringe dimensions, fill volume, formulation viscosity, needle gauge, injection force, plunger performance, and target injection time can all affect device compatibility. Often these device manufacturers have a list of compatible syringe container closure systems which offer a great starting point.
Planning a Vial to Prefilled Syringe Transition?
Argonaut Manufacturing Services supports prefilled syringe programs across clinical and commercial development, with isolator-based aseptic filling, analytical testing, and experience supporting complex and high-value drug products.
For a deeper look at the transition, download our Vial to Prefilled Syringe whitepaper . It covers container closure selection, formulation compatibility, stability testing, CCIT, device considerations, and the steps involved in prefilled syringe tech transfer.
Citations
Korytkowski M, Bell D, Jacobsen C, Suwannasari R; FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003 Nov;25(11):2836-48. doi: 10.1016/s0149-2918(03)80337-5. PMID: 14693308.